Genetic dissection of DNA damage response pathways reveals divergent modulation of PD-1 blockade response in colorectal cancer
Although MSI-H/dMMR colorectal cancers and the rarer subset with pathogenic POLE exonuclease domain mutations can benefit from immune checkpoint blockade,